Cargando...
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. FDA: tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma subtypes (DL...
Guardado en:
| Publicado en: | Blood Rev |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628697/ https://ncbi.nlm.nih.gov/pubmed/30528964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.blre.2018.11.002 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|